23 April 2026

BPC-157 confirmed for Day 1 of the July 23–24 PCAC review alongside KPV, TB-500, and MOTs-C. The Historian notes PCAC recommendations are non-binding — FDA ultimately decides — preserving optionality for career staff to resist political pressure even if the stacked committee recommends Cat 1. The Skeptic's primary falsifier (Kennedy filling 6 PCAC vacancies with pro-access appointees) remains live but unconfirmed. No new evidence warrants an update.

PCAC agenda expanded to seven peptides across two days — Day 2 adds DSIP, Semax, and Epitalon, but the Day 1 basket of four relevant to this forecast is unchanged. A two-day marathon review suggests the committee is prepared for substantive deliberation, not a rubber stamp. The Historian's DSHEA 1994 analogy (batch reclassification under political momentum) continues to support the upside case.

Confirming signals only. Hims's "longevity specialty" product line — peptides, coenzymes, and GLP treatments — is widely reported as a 2026 launch. The stock's 49% five-day surge ahead of May 11 earnings creates corporate accountability to deliver on the peptide thesis. The Augur flags this as double-edged: if earnings disappoint on peptide timeline specifics, correction pressure could slow the launch. EPS expected down 70% YoY creates tension between growth narrative and profitability.

No new incidents. Gray-market contamination data (8% endotoxin in RUO samples, 12–58% in unregulated products) provides underlying fuel, but the fire hasn't started. The confirmed FDA finding — no adverse-event spike from compounded peptides — remains the most material recent signal. An unresolved prior-run divergence (April 22: 0.62 at 10:52 UTC vs 0.65 at 15:30 UTC) persists; the 10:52 run had the FDA signal, the 15:30 run did not. Operator adjudication needed.

No enrollment data — program starts July 1. Extension to December 2027 is modestly positive for "under 1M": CMS is planning for a long ramp. Structural friction confirmed: $50 copay doesn't count toward Part D deductible or OOP cap, Part D sponsors bear no financial risk and have no marketing incentive, providers must verify BMI + comorbidity eligibility. Three eligible medications confirmed (Foundayo, Wegovy, Zepbound KwikPen).

Math unchanged. GLP-1 affiliate CPA (~$260) vs peptide (~$8–40) dominates. FDA's March 2026 batch of 30 warning letters continues GLP-1 compounding crackdown, but Hims-Novo branded deal provides alternative referral pathway. No peptide DTC affiliate programs exist.

Execution forecast — only build progress data can move this, not market signals. 99 days remain. PCAC July 23 creates a natural content marketing window; ideal launch timing is before the meeting. No build progress data available.